Shanghai Menke Pharmaceutical

Menke Pharmaceutical is a clinical-stage biotechnology company headquartered in Shanghai, China, specializing in the development of small molecule drugs for metabolic and chronic diseases. The company's lead program, MK-01, is a highly selective thyroid hormone receptor beta (THR-beta) agonist currently being evaluated for the treatment of non-alcoholic steatohepatitis (NASH). By targeting liver-specific receptors, Menke aims to provide effective treatments for metabolic disorders while reducing the risk of cardiovascular and bone-related side effects. The firm maintains a strong focus on medicinal chemistry and translational medicine to advance its internal pipeline of metabolic and endocrine-focused therapies.